PAHO-Gilead deal expands lenacapavir access in Latin America, reinforcing global Yeztugo runway

What happened

Gilead and the Pan American Health Organization have reached an agreement to expand access to lenacapavir for HIV prevention across 14 Latin American countries, a move welcomed by AIDS Healthcare Foundation as a civil society victory. The deal builds on Gilead's existing Yeztugo (lenacapavir) launch momentum, which has already achieved ~90% U.S. payer coverage and Q1 2026 sales of $166 million, and now extends that franchise into emerging markets. While the specific terms—such as pricing, volume commitments, and implementation timelines—are not disclosed, the agreement signals a tangible step toward capturing the large underserved HIV prevention population outside the U.S. This international expansion complements the near-term catalysts already tracked in the DeepValue thesis, including the BIC/LEN FDA decision on August 27 and the anito-cel PDUFA in December. However, investor attention should remain on converting access deals into paid utilization, as the Latin American market typically has lower pricing power and slower reimbursement dynamics than the U.S., which may limit near-term revenue contribution.

Implication

Investors should view the PAHO-Gilead agreement as a moderate positive that reinforces lenacapavir's global commercial potential without altering the near-term earnings trajectory, which remains dominated by the ~$11.5B acquired IPR&D charge in Q2 2026. The deal's contribution to 2026 revenue will be limited because regulatory approvals and country-level procurement processes in Latin America often take 12–24 months to translate into sales. The core investment thesis still hinges on U.S. Yeztugo utilization and persistence improvements, as well as successful FDA outcomes for BIC/LEN and anito-cel, rather than international deals. That said, successful execution in lower-income regions could enhance Gilead's reputation and create long-term volume streams, potentially supporting a higher terminal value for the HIV prevention platform. We maintain our POTENTIAL BUY rating with an attractive entry around $115, and we will monitor subsequent disclosures for any specific volume or pricing guidance from this Latin American partnership.

Thesis delta

The PAHO agreement introduces a new international access vector for lenacapavir, which modestly strengthens the global PrEP growth case beyond the U.S.-centric assumptions in the DeepValue report. However, it does not change the near-term financial outlook or the key catalysts (Yeztugo utilization, BIC/LEN approval, anito-cel). We keep our conviction of 3.5 and target range unchanged, but now expect a potential upside from emerging market penetration over the medium term.